Editas Medicine Inc EDIT announced initial safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the
Today: 10/06/2023
This is made by Header Builder. You can enter anything here or remove this text. Add any element here with header builder. Using shortcode here is ok, Today: 10/06/2023
Signup to Newsletter
Add any text here or remove it if you want. We've been waiting for you. Where the kisses are hers and hers and his, three's company, too! Come and dance on our floor.
[mc4wp_form id="811"]
Biotechnology
You can enter anything here. Intro, A banner, latest posts, featured posts.. or remove this.
Roche Group Holdings AG’s RHHBY data from the global phase 3 COMMODORE 1 and 2 studies evaluating crovalimab compared to eculizumab, a current standard of
Vertex Pharmaceuticals Incorporated VRTX and CRISPR Therapeutics AG CRSP announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent beta-thalassemia (TDT) or severe sickle cell
AstraZeneca Plc AZN released data from the Phase 3 ALPHA trial of danicopan as an add-on to the standard of care for paroxysmal nocturnal hemoglobinuria
AstraZeneca plc AZN has entered into a collaboration, exclusive option, and license agreement with Quell Therapeutics to develop multiple engineered T-regulator (Treg) cell therapies for Type 1
The FDA’s Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc AZN and Sanofi SA’s SNY nirsevimab has a favorable benefit-risk profile
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism. Strong investigator enthusiasm and continued robust enrollment;
Key Takeaways: Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a
Astellas Pharma Inc ALPMF ALPMY decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as X-linked myotubular myopathy
Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd ESALY/Biogen Inc BIIB Alzheimer’s
Banner
